Human Albumin Injection - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510242599

Publication Date:

October 17, 2024

Pages:

111

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Human albumin solutions are used in a range of medical and surgical problems.
The global market for Human Albumin Injection was estimated to be worth US$ 396 million in 2023 and is forecast to a readjusted size of US$ 549.4 million by 2030 with a CAGR of 5.0% during the forecast period 2024-2030
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Human Albumin Injection, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Human Albumin Injection by region & country, by Type, and by Application.
The Human Albumin Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Albumin Injection.
麻豆原创 Segmentation
By Company
Octapharma
CSL Behring
Biotest (UK) Ltd
Baxter
Kedrion Biopharma, Inc.
Grifols
GE HealthCare
Bio Products Laboratory
Green Cross
SK Plasma
Instituto Grifols
Takeda
Hualan Bio
Nanyue Biopharmaceuticals
Segment by Type:
Blood Extraction
Recombine
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Human Albumin Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Human Albumin Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Human Albumin Injection in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Human Albumin Injection Product Introduction
1.2 Global Human Albumin Injection 麻豆原创 Size Forecast
1.2.1 Global Human Albumin Injection Sales Value (2019-2030)
1.2.2 Global Human Albumin Injection Sales Volume (2019-2030)
1.2.3 Global Human Albumin Injection Sales Price (2019-2030)
1.3 Human Albumin Injection 麻豆原创 Trends & Drivers
1.3.1 Human Albumin Injection Industry Trends
1.3.2 Human Albumin Injection 麻豆原创 Drivers & Opportunity
1.3.3 Human Albumin Injection 麻豆原创 Challenges
1.3.4 Human Albumin Injection 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Human Albumin Injection Players Revenue Ranking (2023)
2.2 Global Human Albumin Injection Revenue by Company (2019-2024)
2.3 Global Human Albumin Injection Players Sales Volume Ranking (2023)
2.4 Global Human Albumin Injection Sales Volume by Company Players (2019-2024)
2.5 Global Human Albumin Injection Average Price by Company (2019-2024)
2.6 Key Manufacturers Human Albumin Injection Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Human Albumin Injection Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Human Albumin Injection
2.9 Human Albumin Injection 麻豆原创 Competitive Analysis
2.9.1 Human Albumin Injection 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Human Albumin Injection Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Albumin Injection as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Blood Extraction
3.1.2 Recombine
3.2 Global Human Albumin Injection Sales Value by Type
3.2.1 Global Human Albumin Injection Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Human Albumin Injection Sales Value, by Type (2019-2030)
3.2.3 Global Human Albumin Injection Sales Value, by Type (%) (2019-2030)
3.3 Global Human Albumin Injection Sales Volume by Type
3.3.1 Global Human Albumin Injection Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Human Albumin Injection Sales Volume, by Type (2019-2030)
3.3.3 Global Human Albumin Injection Sales Volume, by Type (%) (2019-2030)
3.4 Global Human Albumin Injection Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.2 Global Human Albumin Injection Sales Value by Application
4.2.1 Global Human Albumin Injection Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Human Albumin Injection Sales Value, by Application (2019-2030)
4.2.3 Global Human Albumin Injection Sales Value, by Application (%) (2019-2030)
4.3 Global Human Albumin Injection Sales Volume by Application
4.3.1 Global Human Albumin Injection Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Human Albumin Injection Sales Volume, by Application (2019-2030)
4.3.3 Global Human Albumin Injection Sales Volume, by Application (%) (2019-2030)
4.4 Global Human Albumin Injection Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Human Albumin Injection Sales Value by Region
5.1.1 Global Human Albumin Injection Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Human Albumin Injection Sales Value by Region (2019-2024)
5.1.3 Global Human Albumin Injection Sales Value by Region (2025-2030)
5.1.4 Global Human Albumin Injection Sales Value by Region (%), (2019-2030)
5.2 Global Human Albumin Injection Sales Volume by Region
5.2.1 Global Human Albumin Injection Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Human Albumin Injection Sales Volume by Region (2019-2024)
5.2.3 Global Human Albumin Injection Sales Volume by Region (2025-2030)
5.2.4 Global Human Albumin Injection Sales Volume by Region (%), (2019-2030)
5.3 Global Human Albumin Injection Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Human Albumin Injection Sales Value, 2019-2030
5.4.2 North America Human Albumin Injection Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Human Albumin Injection Sales Value, 2019-2030
5.5.2 Europe Human Albumin Injection Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Human Albumin Injection Sales Value, 2019-2030
5.6.2 Asia Pacific Human Albumin Injection Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Human Albumin Injection Sales Value, 2019-2030
5.7.2 South America Human Albumin Injection Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Human Albumin Injection Sales Value, 2019-2030
5.8.2 Middle East & Africa Human Albumin Injection Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Human Albumin Injection Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Human Albumin Injection Sales Value
6.2.1 Key Countries/Regions Human Albumin Injection Sales Value, 2019-2030
6.2.2 Key Countries/Regions Human Albumin Injection Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Human Albumin Injection Sales Value, 2019-2030
6.3.2 United States Human Albumin Injection Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Human Albumin Injection Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Human Albumin Injection Sales Value, 2019-2030
6.4.2 Europe Human Albumin Injection Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Human Albumin Injection Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Human Albumin Injection Sales Value, 2019-2030
6.5.2 China Human Albumin Injection Sales Value by Type (%), 2023 VS 2030
6.5.3 China Human Albumin Injection Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Human Albumin Injection Sales Value, 2019-2030
6.6.2 Japan Human Albumin Injection Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Human Albumin Injection Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Human Albumin Injection Sales Value, 2019-2030
6.7.2 South Korea Human Albumin Injection Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Human Albumin Injection Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Human Albumin Injection Sales Value, 2019-2030
6.8.2 Southeast Asia Human Albumin Injection Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Human Albumin Injection Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Human Albumin Injection Sales Value, 2019-2030
6.9.2 India Human Albumin Injection Sales Value by Type (%), 2023 VS 2030
6.9.3 India Human Albumin Injection Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Octapharma
7.1.1 Octapharma Company Information
7.1.2 Octapharma Introduction and Business Overview
7.1.3 Octapharma Human Albumin Injection Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Octapharma Human Albumin Injection Product Offerings
7.1.5 Octapharma Recent Development
7.2 CSL Behring
7.2.1 CSL Behring Company Information
7.2.2 CSL Behring Introduction and Business Overview
7.2.3 CSL Behring Human Albumin Injection Sales, Revenue and Gross Margin (2019-2024)
7.2.4 CSL Behring Human Albumin Injection Product Offerings
7.2.5 CSL Behring Recent Development
7.3 Biotest (UK) Ltd
7.3.1 Biotest (UK) Ltd Company Information
7.3.2 Biotest (UK) Ltd Introduction and Business Overview
7.3.3 Biotest (UK) Ltd Human Albumin Injection Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Biotest (UK) Ltd Human Albumin Injection Product Offerings
7.3.5 Biotest (UK) Ltd Recent Development
7.4 Baxter
7.4.1 Baxter Company Information
7.4.2 Baxter Introduction and Business Overview
7.4.3 Baxter Human Albumin Injection Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Baxter Human Albumin Injection Product Offerings
7.4.5 Baxter Recent Development
7.5 Kedrion Biopharma, Inc.
7.5.1 Kedrion Biopharma, Inc. Company Information
7.5.2 Kedrion Biopharma, Inc. Introduction and Business Overview
7.5.3 Kedrion Biopharma, Inc. Human Albumin Injection Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Kedrion Biopharma, Inc. Human Albumin Injection Product Offerings
7.5.5 Kedrion Biopharma, Inc. Recent Development
7.6 Grifols
7.6.1 Grifols Company Information
7.6.2 Grifols Introduction and Business Overview
7.6.3 Grifols Human Albumin Injection Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Grifols Human Albumin Injection Product Offerings
7.6.5 Grifols Recent Development
7.7 GE HealthCare
7.7.1 GE HealthCare Company Information
7.7.2 GE HealthCare Introduction and Business Overview
7.7.3 GE HealthCare Human Albumin Injection Sales, Revenue and Gross Margin (2019-2024)
7.7.4 GE HealthCare Human Albumin Injection Product Offerings
7.7.5 GE HealthCare Recent Development
7.8 Bio Products Laboratory
7.8.1 Bio Products Laboratory Company Information
7.8.2 Bio Products Laboratory Introduction and Business Overview
7.8.3 Bio Products Laboratory Human Albumin Injection Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Bio Products Laboratory Human Albumin Injection Product Offerings
7.8.5 Bio Products Laboratory Recent Development
7.9 Green Cross
7.9.1 Green Cross Company Information
7.9.2 Green Cross Introduction and Business Overview
7.9.3 Green Cross Human Albumin Injection Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Green Cross Human Albumin Injection Product Offerings
7.9.5 Green Cross Recent Development
7.10 SK Plasma
7.10.1 SK Plasma Company Information
7.10.2 SK Plasma Introduction and Business Overview
7.10.3 SK Plasma Human Albumin Injection Sales, Revenue and Gross Margin (2019-2024)
7.10.4 SK Plasma Human Albumin Injection Product Offerings
7.10.5 SK Plasma Recent Development
7.11 Instituto Grifols
7.11.1 Instituto Grifols Company Information
7.11.2 Instituto Grifols Introduction and Business Overview
7.11.3 Instituto Grifols Human Albumin Injection Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Instituto Grifols Human Albumin Injection Product Offerings
7.11.5 Instituto Grifols Recent Development
7.12 Takeda
7.12.1 Takeda Company Information
7.12.2 Takeda Introduction and Business Overview
7.12.3 Takeda Human Albumin Injection Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Takeda Human Albumin Injection Product Offerings
7.12.5 Takeda Recent Development
7.13 Hualan Bio
7.13.1 Hualan Bio Company Information
7.13.2 Hualan Bio Introduction and Business Overview
7.13.3 Hualan Bio Human Albumin Injection Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Hualan Bio Human Albumin Injection Product Offerings
7.13.5 Hualan Bio Recent Development
7.14 Nanyue Biopharmaceuticals
7.14.1 Nanyue Biopharmaceuticals Company Information
7.14.2 Nanyue Biopharmaceuticals Introduction and Business Overview
7.14.3 Nanyue Biopharmaceuticals Human Albumin Injection Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Nanyue Biopharmaceuticals Human Albumin Injection Product Offerings
7.14.5 Nanyue Biopharmaceuticals Recent Development
8 Industry Chain Analysis
8.1 Human Albumin Injection Industrial Chain
8.2 Human Albumin Injection Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Human Albumin Injection Sales Model
8.5.2 Sales Channel
8.5.3 Human Albumin Injection Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Octapharma
CSL Behring
Biotest (UK) Ltd
Baxter
Kedrion Biopharma, Inc.
Grifols
GE HealthCare
Bio Products Laboratory
Green Cross
SK Plasma
Instituto Grifols
Takeda
Hualan Bio
Nanyue Biopharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.